{"product_id":"peg-mgf-2mg-pegylated-mechano-growth-factor-research-peptide","title":"PEG-MGF 2mg – Pegylated Mechano Growth Factor Research Peptide","description":"\u003cp\u003e\u003cstrong\u003ePEG-MGF Description\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePEG-MGF is a lab-created version of a natural protein that your body produces when your muscles are stressed or damaged, such as during intense exercise or injury.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIt is derived from Mechano Growth Factor (MGF), a special variant of the growth factor IGF-1 that signals the body to start repairing and building muscle tissue.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eScientists attach a special PEG molecule to MGF to create PEG-MGF, which extends its presence in the body from only minutes to up to two or three days.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis longer duration makes PEG-MGF a more practical and effective tool for supporting ongoing muscle repair and growth.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePEG-MGF primarily activates satellite cells, which are special stem cells located in your muscles that remain dormant until needed for healing.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese satellite cells then multiply, repair damaged muscle fibers, and contribute to new muscle growth through fusion and protein synthesis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAs a result, PEG-MGF helps accelerate recovery from muscle tears, joint injuries, and intense workouts.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIt also shows promise in addressing age-related muscle loss known as sarcopenia, repairing heart tissue after a heart attack, and supporting nerve regeneration after injury.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eMany athletes and bodybuilders use PEG-MGF to enhance muscle growth and shorten recovery time after tough training sessions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIt is often combined with another healing peptide called BPC-157, which makes the muscle, joint, and tissue repair process even more effective.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePEG-MGF Mechanism of Action at the Molecular Level\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePEG-MGF, or Pegylated Mechano Growth Factor, is a synthetic peptide derived from Mechano Growth Factor (MGF), a variant of Insulin-like Growth Factor 1 (IGF-1).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eMGF is naturally produced in response to muscle stress or damage, such as after intense exercise, to promote muscle repair and growth.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePegylation, the process of attaching polyethylene glycol (PEG) to MGF, extends its half-life from 5–7 minutes to 48–72 hours, making it more effective for research and regenerative applications.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAt the biochemical core, endogenous MGF arises as the IGF-1Ec splice variant in humans from the IGF1 gene.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe primary transcript undergoes alternative splicing to include exons 4, 5, and 6, yielding a pro-peptide where the mature IGF-1 domain is followed by a unique 24-amino-acid C-terminal E-domain extension.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis E-domain is the functional moiety in synthetic PEG-MGF preparations used in peptide research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eEnzymatic cleavage releases the bioactive E-peptide, which operates locally in an autocrine\/paracrine manner.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe PEG moiety — typically a 2–5 kDa linear or branched polyethylene glycol chain — is covalently attached via amide linkage to the N-terminus or a lysine residue, sterically hindering proteolytic degradation by serum proteases and reducing glomerular filtration.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis shifts pharmacokinetics from rapid renal clearance to prolonged systemic bioavailability.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eStructural and Pharmacokinetic Foundations Enabling Molecular Activity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe native MGF E-peptide is highly labile due to its short half-life and susceptibility to endopeptidases targeting the QRRK motif.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePegylation introduces hydrophilic ethylene oxide repeats that increase hydrodynamic radius, shield cleavage sites, and minimize immunogenicity while preserving the E-domain’s amphipathic character.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis allows PEG-MGF to distribute effectively to damaged tissues via the bloodstream, where it interacts with satellite cell membranes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn contrast to systemic mature IGF-1, the MGF E-domain exhibits distinct receptor engagement kinetics, often bypassing classical IGF-1R binding epitopes encoded solely in exons 3–4.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eExperimental blockade of IGF-1R with neutralizing antibodies does not abolish E-peptide-driven proliferation in myoblasts or mesenchymal stem cells, confirming an IGF-1R-independent component mediated by the unique C-terminal sequence.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eReceptor Engagement and Proximal Signal Transduction\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eUpon reaching target cells, primarily quiescent Pax7+ satellite cells in skeletal muscle, PEG-MGF initiates signaling through a combination of IGF-1R-dependent and IGF-1R-independent routes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe mature IGF-1-like domain retains low-affinity interaction with IGF-1R, a tyrosine kinase receptor, leading to autophosphorylation at Tyr1135\/1136 in the kinase domain.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis recruits insulin receptor substrate-1 (IRS-1) via its phosphotyrosine-binding domain, phosphorylating IRS-1 at multiple Tyr residues.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDownstream, this bifurcates into two canonical cascades:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003ePI3K\/Akt\/mTOR\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eRas\/Raf\/MEK\/ERK\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThe E-domain, however, drives the majority of satellite-cell-specific effects via a putative non-canonical receptor or co-receptor system.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eEvidence points to interactions with heparan sulfate proteoglycans (HSPGs) on the extracellular matrix or an unidentified G-protein-coupled or tyrosine-kinase-associated receptor.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis leads to rapid activation of mitogen-activated protein kinase (MAPK) pathways, particularly ERK1\/2 and potentially ERK5, without robust Akt phosphorylation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn parallel, protein kinase C (PKC) isoforms are engaged, translocating to the nucleus and phosphorylating Nrf2 at Ser40.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePhospho-Nrf2 dissociates from Keap1, translocates to the nucleus, and binds antioxidant response elements (AREs), upregulating:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eheme oxygenase-1 (HO-1),\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eNAD(P)H quinone dehydrogenase 1 (NQO1),\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eand superoxide dismutase 2 (SOD2).\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThis redox buffering is critical for cytoprotection during oxidative burst post-injury.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAdditional modulation occurs at stress kinase levels: PEG-MGF attenuates p38 MAPK phosphorylation in mechanically overloaded cells, reducing downstream activation of ATF2 and CHOP, thereby inhibiting caspase-3\/9-mediated apoptosis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn cardiomyocytes and neurons, the E-domain also stabilizes 14-3-3 protein interactomes, sequestering pro-apoptotic Bad and FoxO3a, preserving mitochondrial membrane potential and blocking cytochrome c release.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDownstream Molecular Effects on Satellite Cell Dynamics and Myogenesis\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSatellite cells reside in a G0 quiescent state beneath the basal lamina, expressing Pax7 and Myf5.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePEG-MGF binding triggers exit from G0 into G1 via cyclin D1 upregulation and CDK4\/6 activation, driven by ERK-mediated phosphorylation of Elk-1 and subsequent c-Fos\/c-Jun AP-1 transcription.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis proliferative burst expands the myoblast pool while transiently suppressing myogenin and MEF2C, delaying terminal differentiation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe E-peptide thus acts as a “mitogenic gatekeeper,” ensuring sufficient progenitors before fusion.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOnce the local environment shifts, myoblasts express desmin, MyoD, and myogenin, fuse via cadherin-15 and integrin-β1, and donate myonuclei to existing myofibers or form new fibers.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis increases cross-sectional area through sarcomere addition and elevates myosin heavy chain (MHC) isoform expression, particularly MHC-IIx\/d for fast-twitch hypertrophy.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAt the translational level, any IGF-1R\/Akt arm activates mTORC1 via TSC2 inhibition.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003emTORC1 phosphorylates S6K1 and 4E-BP1, enhancing cap-dependent translation of TOP mRNAs encoding ribosomal proteins and elongation factors.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis directly boosts myofibrillar protein accretion.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn parallel, PGC-1α and PPARδ transcription rise, supporting mitochondrial biogenesis for sustained energy during repair.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTissue-Specific Molecular Applications\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn skeletal muscle injury or overload, mechanical stretch induces immediate early expression of IGF-1Ec mRNA within hours via mechanosensitive promoters.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePEG-MGF recapitulates this by recruiting macrophages and neutrophils via MCP-1 and IL-6 modulation to clear debris, then drives satellite cell proliferation to replace lost myonuclei.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe net outcome is:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eaccelerated fiber regeneration,\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ereduced fibrosis,\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003elower TGF-β1\/Smad3 activity,\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eand hypertrophy-associated signaling.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eFor sarcopenia, age-related decline in MGF transcript response to loading correlates with satellite cell senescence and reduced Notch signaling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eExogenous PEG-MGF restores proliferative lifespan by upregulating telomerase reverse transcriptase (TERT) and downregulating p16INK4a\/p21.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis expands the progenitor pool and counters myofiber atrophy.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePost-myocardial infarction, hypoxic cardiomyocytes upregulate MGF locally.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePEG-MGF administration inhibits hypoxia-induced apoptosis via PKC-Nrf2-HO-1 and 14-3-3 stabilization, preserving left-ventricular ejection fraction and reducing infarct size.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIt also promotes limited cardiomyocyte cell-cycle re-entry and angiogenesis via VEGF crosstalk, supporting scar remodeling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn peripheral nerve injury, PEG-MGF supports Schwann cell proliferation and axonal sprouting.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe Nrf2\/HO-1 axis mitigates oxidative damage at the injury site, while ERK signaling enhances neurite outgrowth via GAP-43 and β-III-tubulin expression.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNeuroprotective effects extend to central nervous system models, reducing neuronal loss in oxidative stress paradigms.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eJoint and tendon injuries benefit indirectly: satellite-cell-derived myoblasts and paracrine factors improve peri-articular muscle support, while anti-inflammatory modulation limits chronic synovitis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSynergistic Molecular Enhancement with BPC-157\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBPC-157 complements PEG-MGF through orthogonal pathways, making the combination relevant in muscle, joint, and tissue repair research models.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eWhile PEG-MGF drives myogenic progenitor expansion via E-domain\/ERK\/PKC cascades, BPC-157 upregulates growth hormone receptor (GHR) and VEGF-A\/VEGFR2 signaling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis activates endothelial nitric oxide synthase (eNOS) via Akt and FAK pathways, boosting nitric oxide production, angiogenesis, fibroblast migration, and collagen I\/III deposition at injury sites.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBPC-157 also modulates COX-2\/LOX pathways to resolve inflammation without glucocorticoid-like suppression, preserving the early macrophage influx required for MGF-induced repair.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAt the integrative level, BPC-157’s FAK-ERK axis primes extracellular matrix remodeling, facilitating satellite cell migration and fusion enhanced by PEG-MGF.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn tendon and ligament models, BPC-157 increases tenocyte proliferation and type-I collagen cross-linking, while PEG-MGF supports overlying muscle regeneration.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn sarcopenia models, the combination supports both vascular supply and myonuclear addition.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePost-myocardial infarction research suggests BPC-157’s cardioprotective nitric oxide and angiogenic effects may complement MGF’s anti-apoptotic Nrf2 signaling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFor nerve crush or transection models, combined neurotrophic support may accelerate axonal regrowth and remyelination through complementary BDNF\/TrkB and ERK\/GAP-43-associated pathways.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eApplication strategies in peptide research often pair PEG-MGF with BPC-157 in muscle recovery and regenerative protocols.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe extended half-life of PEG-MGF allows less frequent administration while BPC-157 provides sustained anti-inflammatory and angiogenic support.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIntegrated Regenerative Implications\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePEG-MGF’s prolonged systemic action via pegylation, coupled with its dual IGF-1R-dependent and E-domain-driven IGF-1R-independent signaling, positions it as a precision tool for targeted regeneration.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIts mechanisms include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eprotein synthesis via PI3K\/Akt\/mTOR,\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003esatellite cell proliferation via MAPK\/ERK,\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eredox protection via PKC-Nrf2,\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003emuscle regeneration,\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eangiogenesis-associated support,\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ematrix remodeling,\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eand tissue resilience.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eWhen combined with BPC-157, the molecular orchestration of myogenesis, angiogenesis, matrix remodeling, and redox homeostasis may produce synergistic outcomes in models of:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003emuscle wasting,\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eischemic cardiac damage,\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eneural trauma,\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ejoint injury,\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eand tendon stress.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eOngoing biochemical investigation of the exact E-domain receptor and its nuclear interactors may further refine synthetic analogs for clinical peptide research pipelines.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis framework aligns with applications in muscle and joint trauma, sarcopenic muscle loss, post-infarct recovery, and post-nerve injury repair, offering a mechanistic basis for regenerative peptide research protocols.\u003c\/span\u003e\u003c\/p\u003e","brand":"PRG","offers":[{"title":"Vial","offer_id":53119417614602,"sku":null,"price":140.0,"currency_code":"EUR","in_stock":true},{"title":"Pre-filled Pen","offer_id":53119417647370,"sku":null,"price":165.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0908\/7113\/6522\/files\/peg_2.png?v=1779960601","url":"https:\/\/www.peptideregenesis.com\/it\/products\/peg-mgf-2mg-pegylated-mechano-growth-factor-research-peptide","provider":"PRG","version":"1.0","type":"link"}